Evidence map›Paper›PMID 35890075›Full record

ArticlePharmaceuticals (Basel, Switzerland)2022

Therapeutic Efficacy of

Sara M Robledo, Javier Murillo, Natalia Arbeláez, Andrés Montoya, Victoria Ospina, Franziska M Jürgens, Iván D Vélez, Thomas J Schmidt

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Review
  3. RNA modification is the mark and strategy for host-microbe interactions.Cellular and molecular life sciences : CMLS · 2025
    Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Sara M RobledoPECET-School of Medicine, University of Antioquia, Calle 70 # 52-21, Medellin 0500100, Colombia.ORCID 0000-0003-2752-4931
Javier MurilloPECET-School of Medicine, University of Antioquia, Calle 70 # 52-21, Medellin 0500100, Colombia.
Natalia ArbeláezPECET-School of Medicine, University of Antioquia, Calle 70 # 52-21, Medellin 0500100, Colombia.
Andrés MontoyaPECET-School of Medicine, University of Antioquia, Calle 70 # 52-21, Medellin 0500100, Colombia.
Victoria OspinaPECET-School of Medicine, University of Antioquia, Calle 70 # 52-21, Medellin 0500100, Colombia.
Franziska M JürgensUniversity of Münster, Institute of Pharmaceutical Biology and Phytochemistry, PharmaCampus, Corrensstrasse 48, D-48149 Münster, Germany.ORCID 0000-0003-4980-6227
Iván D VélezPECET-School of Medicine, University of Antioquia, Calle 70 # 52-21, Medellin 0500100, Colombia.
Thomas J SchmidtUniversity of Münster, Institute of Pharmaceutical Biology and Phytochemistry, PharmaCampus, Corrensstrasse 48, D-48149 Münster, Germany.ORCID 0000-0003-2634-9705
Universidad de Antioquia · COUniversity of Münster · DE

Funding

Wilhelm Doerenkamp-Foundation NATVANTAGE RESEARCH GRANT 2018
6 · The paper itself

Abstract

Leishmaniasis may occur in three different clinical forms, namely, visceral, mucocutaneous and cutaneous, which are caused by different species of trypanosomatid protozoans of the genus

Indexed as

antileishmanial drugsArnica montana L.Arnica tincturecutaneous leishmaniasisLeishmania braziliensisLeishmania tropicaMesocricetus auratusnatural productssesquiterpene lactones

Identifiers

PMID35890075
PMCPMC9321785
OpenAlexW4283325316

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.